How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases? [PDF]
Spataro F +5 more
europepmc +1 more source
Altered blood-brain barrier transport of nanotherapeutics in lysosomal storage diseases. [PDF]
Solomon M +6 more
europepmc +1 more source
A low dose of dexmedetomidine, delivered by ROS‐responsive nanoparticles, preferentially accumulates in the ischemic intestine and restores gut vascular barrier integrity after ischemia/reperfusion injury. This nanoparticle‐based strategy prevents bacterial translocation and liver damage without cardiorespiratory side effects, working through HDAC ...
Hu‐Fei Zhang +10 more
wiley +1 more source
Secondary accumulation of lyso-platelet activating factors in lysosomal storage diseases. [PDF]
Kell P +10 more
europepmc +1 more source
The Antifungal Antibiotic Filipin as a Diagnostic Tool of Cholesterol Alterations in Lysosomal Storage Diseases and Neurodegenerative Disorders. [PDF]
Bruno F +3 more
europepmc +1 more source
A pathology‐informed engineering strategy rescues reconstituted HDL from inflammatory dysfunction in sepsis. By integrating a ceria nanozyme‐celastrol coordination complex, the platform preserves HDL structure and endotoxin handling, sustains hierarchical intracellular delivery, and enhances immunoregulation across pathological models, translating ...
Han Zhou +12 more
wiley +1 more source
A systematic review of economic evaluations of enzyme replacement therapy in Lysosomal storage diseases. [PDF]
Katsigianni EI, Petrou P.
europepmc +1 more source
Lysosomal Storage Diseases—Regulating Neurodegeneration
Rob U. Onyenwoke, Jay E. Brenman
doaj
Unifying biology of neurodegeneration in lysosomal storage diseases. [PDF]
Ludlaim AM, Waddington SN, McKay TR.
europepmc +1 more source
Detection of Structural Variants by NGS: Revealing Missing Alleles in Lysosomal Storage Diseases. [PDF]
La Cognata V, Cavallaro S.
europepmc +1 more source

